"God's Drug" Redsewey Final Pricing Announcement! $390 per bottle fell short of Wall Street expectations.

On June 29th Gilead Sciences announced the price of its new crown drug, RedseweIn an open letter, Daniel O'Day, the company's chairman and chief executive, said that in the face of global needs, Gilead had set the price of Redsiwe to supply to developed-country governments at $390 a bottle, in order to ensure broad and fair access to drugsbased on the current treatment model, the vast majority of patients are expected to receive five days of treatment, which will use six bottles of Ridsivir, which is equivalent to a course of treatment of $2,340 per patient, or about 165,000 yuanAt the same time, the price for private insurance companies in the United States will be $520 per bottle, about $3,120 a course of treatment, or about 22,000 yuanRedsewe has been the focus of attention since the outbreak of the New Crown outbreak, and in addition to the efficacy, prices are also the focus of attentionin the United States, two authorities, Wall Street and ICER, have given their own price forecasts or recommendationsThe report on drug pricing published by the American Institute of Clinical and Economic Review (ICER) has considerable influence in academia and industry and may have a direct impact on the market price of prescription drugs in the United Statesin a new report last week, ICER found Redsewey to be cost-effective, with treatment costing between $4,580 and $5,080 per patientBut at the same time, ICER believes that if the low-cost dexamethase is approved, Redsewe's price will be cut to $2,520 to $2,800 per courseThis month British researchers published data from the clinical study of dexamethasone, suggesting that the drug could become an effective anti-neo-coronaon the other hand, Gilead's final price was also lower than Wall Street analysts had predictedThe $5,000 is a fairprice price backed by Wall Street analysts, and SVB Leerink, a US investment bank, recently estimated that Redsewe's sales could reach $1.9bn this year and peak at $7.6bn in 2022but other analysts say Redseywe won't generate much revenue in the short term, especially during the pandemicGilead expects to sell 1.5 million courses of drugs by 2020, and about $2.3 billion in revenue at a government price of $2,340, brian Abrahams, an analyst at RBC, said in a report MondayNotably, Gilead is expected to spend about $1 billion on the drug in 2020 alonebut it is very important that if new coronal vaccines are developed globally, or other proven better treatments, Redsewe's growth space will also have to be affecteda clinical trial of the drug, sponsored by the National Institutes of Health (NIH), showed that about 1,000 patients admitted to hospital with new crowns could reduce their average length of stay by up to four days after receiving treatment, and Gilead said these early discharges would save the hospital about $12,000, so the current pricing would add value to the health system, even without taking into account the benefits to patients themselvesat the same time, Gilead says there is no precedent for current pricing, but it is "right and responsible" for pricing at a price that is well below its value: the decision was made in part to eliminate the need for countries to negotiate pricesWe have reduced prices to levels that are affordable for the least developed countries with the lowest purchasing powerThis price will apply to all developed country governments around the world that have approved or authorized the use of Redsewe, Gilead said it had reached an agreement with generic drug makers to make them available at a lower price to ensure accessibilityTo date, Gilead Sciences has entered into voluntary licensing agreements with nine generic drug manufacturersTwo generic stakes companies, Hetero Labs and Cipla, will launch generics at prices of 5,000-6000 rupees ($65-$78) and 3,000-4,000 rupees ($39-42) per 100 milligrams, respectivelybut there is still a dispute over Redsewey's efficacy" did not speed up the recovery of COVID-19, nor did it reduce the fatality rateThe findings came from the world's first randomized, double-blind, placebo-controlled, multi-center clinical trial of the new coronapneumonia (COVID-19) antiviral drug Redsiwe, published online April 29 in the international medical journal The Lancet" The trial found that although Redsewe was safe and well tolerated, there were no significant benefits compared to placebosCao Bin, vice president of the Sino-Japanese Friendship Hospital, which led the study, said in an interviewProfessor John Norrie of the University of Edinburgh (who was not involved in the study) commented in a paper published in The Lancet at the same time: "This study is well-designed as a double-blind, placebo-controlled, multicenter randomized trial, well implemented, with high programme compliance and minimal absence of visits"
, but coincidentally, on April 29th, the U.Sand Chinese research teams published three clinical trial results from Redsewe on April 29th, with differing conclusions U.S researchers believe that Redsewe has a significant positive effect on shortening the recovery time Director of the National Institute of Allergy and Infectious Diseases (NIAID) said Redsewe ewhotreed a randomized double-blind controlled trial in NIAID that showed efficacy that could moderate the recovery of patients infected with the new coronavirus On the same day, Gilead also announced the results of an open-label phase III clinical trial that showed that patients who received a five-day course of treatment with Redsewe had a similar clinical improvement to those who received a 10-day Redsewecourse course based on the positive conclusions of the U.S study, on May 1, the FDA issued an Emergency Use Authorization (EUA) for the treatment of new coronary pneumonia for Reedsywe, who is still in the study, to treat severe patients with suspected or confirmed new coronary pneumonia, including adults and children questioned the difference in conclusions in Sino-US clinical trials, Cao Bin's view is that the evaluation criteria are different John Norrie points out that while the Chinese experiment was well designed, it ended early and there was "insufficient support" for the results Gilead says Redsewey's approvals vary from country to country, based on current public health emergencies and available clinical data In countries where local health agencies have not approved Redsewe, Redsewe is still working on the drug, and its safety and efficacy are not yet clear But the company will continue to explore the possibility of helping in different ways in this outbreak, such as evaluating interventional treatment at an early stage of the disease, in outpatient settings, through inhalation agents, applications in more patient populations, and combination therapies with other drugs the controversy continues globally, even though the FDA has now granted emergency use of the drug.